Flexen

Quick links to important sections

Flexen

Selected form

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Flexen

Quick Facts about Flexen

Property Description
Active ingredient Ketoprofen (INN)
Pharmacological Class Nonsteroidal Anti-Inflammatory Drug (NSAID)
Origin Synthetic (Propionic acid derivative)
Key Forms Capsules, tablets, solution for injection, gel, suppositories
General Purpose Relieves pain, inflammation, and fever

What is the Medicine Flexen and What is it Made Of?

Flexen is a medicinal product defined by its single, therapeutically active component, Ketoprofen. This substance is a compound of synthetic origin, chemically categorized as a propionic acid derivative.

Flexen is clinically recognized for its versatility in delivery, being formulated into oral preparations like capsules and tablets, as well as specialized forms such as a solution for injection, a topical gel, and suppositories. The variety of these forms ensures the product can be administered via different routes—oral, parenteral, dermal, or rectal—depending on whether systemic or localized action is required for managing symptoms.


What Type of Pharmacological Drug is Flexen?

Flexen is officially classified as a Nonsteroidal Anti-Inflammatory Drug (NSAID), a major therapeutic group for its triple-action profile. As a nonselective NSAID, its core principle is the inhibition of prostaglandin synthesis, thereby disrupting the chemical cascade that triggers pain and swelling.

The medicine delivers a potent anti-inflammatory effect to reduce swelling, an analgesic effect for pain relief, and an antipyretic effect for lowering elevated body temperature. Its general purpose is thus to provide comprehensive symptomatic relief by targeting the body's inflammatory signals.

What side effects are possible with Flexen?

Safety Profile Summary

Flexen, as a nonsteroidal anti-inflammatory drug (NSAID), carries documented risks primarily related to cardiovascular and gastrointestinal systems, as required by regulatory authorities like the EMA and FDA for this class of medicine.

Serious and Clinically Significant Adverse Reactions

The most serious documented safety concern is an increased risk of arterial thromboembolic events, which includes the potential for myocardial infarction (heart attack) and stroke. This risk can occur early in treatment and may increase with higher doses and longer duration of use. Additionally, an increased risk of congestive heart failure has been observed.

Serious gastrointestinal events, such as bleeding, ulceration, and perforation of the stomach or intestines, are also known risks associated with the NSAID class.

Population-Specific Safety Considerations

The use of Flexen is contraindicated in patients with established congestive heart failure (NYHA class II–IV), ischemic heart disease, peripheral arterial disease, or cerebrovascular disease. It is also contraindicated in those with a history of gastrointestinal bleeding or ulceration related to previous NSAID therapy.

Patients with significant risk factors for cardiovascular events (e.g., hypertension, high cholesterol, diabetes, or who smoke) require careful clinical consideration before treatment initiation.

Safety Minimization Measures

To mitigate potential risks, official regulatory documents stress that Flexen should be used at the lowest effective dose for the shortest duration necessary to achieve the therapeutic objective. The cardiovascular risks are understood to be dose- and duration-dependent, and the safety of the drug requires ongoing assessment of the individual patient’s benefit-risk balance. Severe skin reactions, such as Stevens-Johnson syndrome, are also documented for this drug class.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory profile for Flexen (Ketoprofen) overdose documents clinical manifestations across the gastrointestinal and central nervous systems. Initial presentations may be limited to symptoms such as nausea, vomiting, abdominal pain, diarrhea, headache, drowsiness, dizziness, and ringing in the ears.

However, a severe overdose—which regulatory labeling defines as potentially five to ten times the usual dose—can lead to severe, life-threatening outcomes. Documented severe manifestations include acute renal failure, severe gastrointestinal bleeding, hypertension or hypotension, respiratory depression, seizures, and coma. Official documents indicate a large overdose carries a risk of serious damage for both adults and children.

Due to the potential for these severe systemic effects, immediate action is required. Government regulatory guidance mandates that individuals seek medical help right away or contact emergency services and a poison control center immediately upon suspected overdose.

Management is based solely on supportive and symptomatic treatment, as no specific antidote is known for Ketoprofen overdose. Hospital monitoring is required, often for a minimum of 4 to 8 hours depending on the product formulation. Procedures such as gastric lavage or activated charcoal may be indicated, and treatment focuses on managing complications like GI bleeding, convulsions, or kidney dysfunction.

Therapeutic Uses of Flexen

What Flexen Treats: Main Uses and Benefits

Flexen is generally used to provide supportive symptomatic relief across conditions presenting with acute or disruptive symptom patterns. The medicine is applicable within clinical settings that involve acute discomfort, chronic inflammation, or episodic pain.

Core Therapeutic Contexts

The medication helps address symptom clusters that may become intense or disruptive, including pronounced pain, swelling, and persistent joint stiffness. It is relevant in conditions characterized by periods of heightened symptoms, such as osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis, and is commonly used to help with acute episodes like gouty arthritis and tendinitis. Furthermore, it is applied for managing pain associated with soft tissue injuries, postoperative or dental procedures, and the discomfort of menstrual cramps.

The primary intent of this use is to ease distress. It is commonly used to help with the overall symptom load, supporting patients during difficult episodes. The medicine also helps address symptoms related to systemic imbalance by addressing elevated body temperature (fever) and generalized body aches. This supportive relief contributes to a sense of stability when symptoms are more noticeable.


Quick Fact: Relief for Key Symptoms
Flexen is considered relevant for easing joint pain, swelling, stiffness, headaches, menstrual cramps, and fever.

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Flexen is an NSAID subject to strict population eligibility and non-eligibility rules established in official regulatory documents.

Contraindicated Populations (Must Not Use)

Use of Flexen is contraindicated and prohibited for patients with:

  • A known allergy or hypersensitivity to Ketoprofen, aspirin, or other NSAIDs.
  • Active peptic ulcer disease or a history of gastrointestinal bleeding or perforation.
  • Treatment of perioperative pain in the setting of Coronary Artery Bypass Graft (CABG) surgery.
  • Pregnancy at 30 weeks gestation or later (third trimester).

Age and Physiological Restrictions

Population Group Regulatory Status
Pediatric Patients (Under 18) Use Not Established. Safety and effectiveness have not been established; not approved for use.
Older Adults (e.g., Over 75) Conditional Use. May require careful monitoring and adjustment due to altered drug clearance.
Pregnancy (20–29 weeks) Avoidance Recommended. Use should be limited due to risk of fetal harm.
Lactating Women Not Recommended. Due to insufficient data on infant risk and reports of adverse effects in breastfed infants.

Organ Function Limitations

Conditional use and close monitoring are required for patients with severe renal impairment or hepatic impairment, with a restricted maximum daily dosage often specified in the labeling.

What should I know about interactions with other medicines?

The interaction profile for Flexen (Ketoprofen) is formally defined by regulatory bodies through specific constraints on co-administration. The combination with other Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), including high-dose salicylates, is officially contraindicated due to the high additive risk of gastrointestinal damage and hemorrhage. Furthermore, Ketoprofen is prohibited for use in the peri-operative setting of Coronary Artery Bypass Graft (CABG) surgery.

Clinically significant pharmacodynamic interactions exist with medicines that affect bleeding. Co-administration with Oral Anticoagulants, Antiplatelet Agents, Oral Corticosteroids, or Selective Serotonin Reuptake Inhibitors (SSRIs) increases the documented risk of bleeding events. Pharmacokinetic interactions require close monitoring for certain drugs, as Ketoprofen reduces the renal clearance of both Lithium and Methotrexate, leading to elevated plasma concentrations. Regulatory documents mandate that Ketoprofen must not be administered less than 12 hours before or after the end of a Methotrexate treatment.

Additionally, Ketoprofen can functionally interfere with Diuretics and ACE Inhibitors/ARBs, which may diminish their intended effects and increase the documented risk of acute renal failure. Intake of alcohol is a risk factor that heightens the hazard of gastrointestinal bleeding. For oral forms, co-administration with food only slows the rate of absorption but does not alter total exposure. The topical (gel) formulation has a low risk of systemic interactions due to low plasma concentrations.

Mechanism of Action

Enzyme Inhibition and Eicosanoid Pathway Modulation

The primary action of Flexen is the reversible, non-selective inhibition of the Cyclooxygenase (COX) enzymes, specifically COX-1 and COX-2 isoforms. This molecular interaction interrupts the initial phase of the Arachidonic Acid Cascade, suppressing the synthesis of various prostaglandins . This mechanism results in the suppression of the inflammatory response by limiting the production of these chemical factors.

Modulating Pain Signaling and Central Thermoregulation

A crucial downstream effect of reduced prostaglandin production is the desensitization of peripheral nociceptors (pain-sensing neurons), which raises the threshold required to activate these fibers, resulting in altered afferent nociceptive signaling. Furthermore, the mechanism extends to the central nervous system (CNS), where the suppression of prostaglandins in the hypothalamus allows the resetting of the core body temperature set point, enabling the body's natural mechanisms to correct the elevated core temperature.

️ Mechanism Specificity and Constraints

Flexen engages mechanisms that modulate the activity of specific signaling pathways. The non-selective inhibition of the constitutive COX-1 enzyme is a fundamental aspect of the molecule's mechanism, which simultaneously reduces the production of prostaglandins required for normal physiological functions, such as TXA2 synthesis and local cytoprotection.

Dosage and Administration Information

How to Use Flexen (Ketoprofen): Official Administration Guidelines

Flexen is formally administered via oral and cutaneous routes, reflecting its availability as immediate-release (IR) and extended-release (ER) capsules, as well as a topical gel.

Standard Dosing Regimens and Frequency

Oral dosing varies based on the formulation and intended use pattern. Immediate-release capsules are typically taken multiple times a day (TID or QID), with a maximum total daily dose of 300 mg. For chronic treatment, the extended-release capsule is prescribed for once-daily (QD) administration, with a maximum dose of 200 mg per day. The official usage protocol mandates employing the lowest effective dose for the shortest duration necessary.

Contextual Administration Instructions

Oral preparations may be taken with food, milk, or antacids and must be swallowed with a full glass of water. It is a procedural requirement that the patient remains upright and does not lie down for at least 10 minutes after ingestion to ensure proper drug passage. The ER capsules must be swallowed whole and are not recommended for managing acute pain episodes.

Population-Specific Dose Adjustments

Official labeling specifies a requirement for a reduced initial dose when administering Flexen to older adults. For patients with severe renal or hepatic impairment, the maximum allowable total daily dose is formally restricted to 100 mg. If a scheduled dose is missed, instructions advise taking it as soon as remembered, but never doubling the dose.

This protocol defines the standardized, label-based approach for using the medicine.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Flexen (Ketoprofen)

Evidence for Chronic Joint and Inflammatory Conditions

Clinical research for conditions like osteoarthritis and rheumatoid arthritis was studied for how symptoms change over time. Studies exploring the use of Flexen in these conditions include Randomized Controlled Trials (RCTs) and systematic reviews that combine findings from multiple trials. Research examined what was measured in studies, including patient-reported outcomes describing perceived discomfort, such as pain intensity scores, and outcomes related to daily functioning, such as measurements of joint stiffness and mobility. Studies describe patterns observed in the studies related to how symptoms were reported in the observed populations during the defined follow-up periods.

Evidence for Acute Systemic and Post-Procedure Pain Relief

Research exploring short-term symptom changes, such as pain following dental or surgical procedures, often utilizes single-dose Randomized Controlled Trials (RCTs). Key outcomes studied include the time it took for patients to report the onset of relief and the total pain reported over the first few hours following administration. Research highlights changes measured during these short-term study periods, often showing patterns related to the time to reported relief and the measured frequency of supplementary pain medication in the immediate aftermath of an acute event.

Areas of Research Uncertainty and Study Gaps

Long-term effects are not fully established beyond short-to-intermediate trial durations, especially concerning sustained functional outcomes. Research providing insight into outcomes beyond several months is more limited, often relying on observational data rather than structured, controlled trials. Data for certain groups remain insufficient. For instance, evidence is limited for the pediatric population. The consistency of findings varies across studies, and comparative evidence is limited.

Key Studies & References

  1. Ketoprofen: MedlinePlus Drug Information (Regulatory/Authoritative Patient Information)

Frequently Asked Questions (FAQ)

Common questions about Flexen (FAQ)

Q: Why would a doctor choose Flexen over similar over-the-counter pain relievers?

Flexen (Ketoprofen) is classified as a non-steroidal anti-inflammatory drug (NSAID). Unlike many over-the-counter options, Flexen is typically available by prescription and is formally indicated for the management of specific types of arthritis and short-term pain relief.


Q: Is Flexen effective for pain that is not related to inflammation?

Flexen’s primary action is the reduction of inflammation, but its official documentation also describes effects on pain-sensing neurons. While the label lists nervous system adverse reactions like headaches, this information does not provide direct evidence for its intended use in non-inflammatory pain.


Q: What is the typical timeframe for a course of Flexen treatment?

Official regulatory guidance directs that Flexen be used at the lowest effective dose for the shortest duration necessary. Formulations exist for both acute (short-term) pain and extended-release for chronic conditions like arthritis. The full duration of treatment is guided by a healthcare professional based on the specific condition.


Q: Is it normal to notice a difference after only one day of taking Flexen?

The immediate-release form of Flexen is officially indicated for the management of acute, short-term pain. Clinical studies for this use measure the onset of relief, which often indicates an effect within the first few hours of administration.


Q: What are the signs of a serious or rare allergic reaction to Flexen?

Regulatory documents describe a serious allergic reaction (anaphylactoid reaction) to Flexen as potentially involving difficulty breathing, and swelling of the face or throat. If these signs are observed, regulatory instructions advise seeking immediate emergency medical help.


Q: Should I avoid any specific foods while taking Flexen?

Regulatory information indicates that oral preparations of Flexen may be taken with food, milk, or antacids. Although food is noted to slow down how quickly the medicine is absorbed, official documentation does not mandate the avoidance of specific foods.


Q: What common over-the-counter cold and flu medicines should I check for Flexen interactions?

Official drug labels warn against combining Flexen with other non-steroidal anti-inflammatory drugs (NSAIDs) or high-dose salicylates. These ingredients may be found in over-the-counter cold and flu preparations, and patients are advised in official documents to review concurrent use of non-prescription products with a healthcare professional.


Q: How long should I wait after stopping Flexen before taking an interacting medicine?

The regulatory label specifies a constraint for the drug Methotrexate, stating that Flexen must not be administered less than 12 hours before or after that treatment ends. The label does not provide a general waiting period for all other interacting medicines.


Q: Is Flexen suitable for people who already have high blood pressure?

Official warnings state that NSAIDs like Flexen can potentially lead to new onset of high blood pressure (hypertension) or worsen pre-existing hypertension. Regulatory documents indicate that caution is advised for use in individuals with pre-existing fluid retention or high blood pressure.


Q: Does Flexen have a Boxed Warning (Black Box Warning) from the FDA or similar agency?

Yes, the official FDA label includes a Boxed Warning, which is a required statement about serious risks. This warning concerns the potentially increased risk of serious cardiovascular thrombotic events (such as myocardial infarction and stroke) and serious gastrointestinal events (including bleeding and ulceration).


Q: What does the term 'non-steroidal' mean in relation to Flexen?

Flexen is classified as a Non-Steroidal Anti-Inflammatory Drug (NSAID). This means it is a type of medicine used to reduce inflammation, pain, and fever that is chemically distinct from and not a corticosteroid, which is a different class of anti-inflammatory drugs.


Q: How long does the effect of one dose of Flexen typically last?

The elimination half-life of the active ingredient, Ketoprofen, has been reported in official documents to be approximately 2 to 2.5 hours in adults. The half-life is a measure of how quickly the body clears the medicine.


Q: Does Flexen build up in the body over time?

Pharmacokinetic data suggests that in older adults taking the drug as prescribed, no drug accumulation occurs in the plasma. However, official labeling notes that a reduced dose may be required for patients with impaired kidney function to help prevent potential accumulation.


Q: What is the average half-life of Flexen?

The elimination half-life of the active ingredient in Flexen, Ketoprofen, has been reported in regulatory documents to be approximately 2 to 2.5 hours in adults.


Q: Can Flexen cause me to feel dizzy or lightheaded during the day?

Dizziness is listed in the official drug documentation as a common adverse reaction related to the Nervous System. It was reported by a percentage of patients in clinical trials.


Q: Is it common to have mild nausea when first starting Flexen?

Nausea is listed as a common Digestive adverse reaction in the official product information. It was reported by 3% to 9% of patients during clinical trials.


Q: Does Flexen cause weight gain or changes in appetite?

Official adverse reaction lists indicate that weight gain is a less common Metabolic and Nutritional reaction, reported by less than 1% of patients. Anorexia, which is a loss of appetite, is listed as a more common reaction.


Q: Does Flexen affect my sleep, and can it cause insomnia?

Insomnia (trouble sleeping) is listed in the official documentation as a common adverse reaction. This effect is generally classified under Central Nervous System (CNS) excitation and was reported by a percentage of patients in clinical trials.


Q: Can Flexen change my mood or cause feelings of anxiety?

The official adverse reaction lists include nervousness and depression as common reactions (reported by 1% to 10% of patients). Anxiety and confusion are also noted as less common or rare reactions.


Q: Can Flexen cause headaches to become more frequent or severe?

Headache is listed as a common adverse reaction, reported by 3% to 9% of patients in clinical trials. Migraine is also noted in the documentation as a less common reaction.


Q: Is Flexen known to cause ringing in the ears (tinnitus)?

Tinnitus (ringing in the ears) is listed in official documentation as a common adverse reaction. This is noted under the Special Senses category in the product information.


Q: Can herbal supplements or vitamins interact with Flexen?

Official regulatory documents warn about interactions between Flexen and various classes of prescription medicines. For non-prescription products, including herbal supplements and vitamins, official regulatory documentation suggests that concurrent use is a topic to be reviewed with a healthcare professional.


Q: Will Flexen interact with my medication for diabetes?

Caution and monitoring are specifically advised in official documentation when Flexen is used alongside the diabetes drug Metformin. This combination carries a potential for an increased risk of lactic acidosis, particularly if the individual has impaired kidney function.


Q: Does Flexen affect the results of any common laboratory blood tests?

Official documentation notes that borderline elevations of one or more liver function tests may occur in some patients taking Flexen.


Q: Is Flexen contraindicated for patients with asthma or nasal polyps?

Flexen is contraindicated for individuals with a history of asthma, hives (urticaria), or allergic-type reactions to aspirin or other NSAIDs. Regulatory documents state that patients whose asthma is complicated by nasal polyps may be at higher risk for these reactions.

How should Flexen be stored and disposed of?

Based on official government regulatory documents for insulin products supplied in the FlexPen delivery system, the following storage and disposal requirements must be followed.

Official Storage Requirements

Condition Unused/Unopened Pen In-Use Pen
Temperature Store in a refrigerator (2 C to 8 C). Store below 30 C (e.g., at room temperature) OR in a refrigerator.
Stability Period Until the expiration date. Discard after 4 to 6 weeks (product-specific) regardless of remaining product.
Freezing/Light Do not freeze. Do not freeze. Keep the pen cap on to protect from light.

Official Disposal Rules

Handling: Needles must be removed after each injection and never shared.

Disposal: Any used needles or other sharps must be placed immediately in a puncture-resistant sharps disposal container. All containers and the medication itself must be kept out of the sight and reach of children. Unused medication and waste material should be disposed of in accordance with local regulatory requirements.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Flexen found in:

A-Z Index: